RUNX1 and acute myeloid leukemia: AML has been thought to clinically develop when a pre-leukemic clone emerges with NPM1, DNMT3A, IDH, RUNX1, FLT3, or RAS mutations, which are identified with a frequency of more than 10%, and when additional founder mutations occur [12].